Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

T-Cell Depletion

CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study

Bone Marrow Transplantation volume 34, pages 123–128 (2004)Cite this article

Summary:

A CD8 murine monoclonal antibody-coated high-density microparticle (HDM) has been developed, which allows for the rapid depletion of CD8+ T cells from apheresis products by gravity sedimentation. We conducted a study to determine the efficacy and safety of CD8 depletion of donor lymphocyte infusions (DLI) to treat relapse after stem cell transplantation using the Eligix CD8-HDM Cell Separation System. Patients were targeted to receive 3 × 107 CD4+ T cells/kg. Nine patients were enrolled, three with CML, three myeloma, two CLL, and one NHL. A median of 1 × 1010 mononuclear cells were obtained by apheresis and processed. The median depletion of CD8+ cells was 99.3% (97.8−>99.5%). CD8 depletion was highly specific, with a median recovery of CD4+ cells of 75%. A median of 2.9 × 107 CD4+ cells/kg was infused. No infusional toxicity was noted. All CML patients achieved a complete molecular remission. A CLL patient demonstrated a complete response. One patient developed GVHD (grade II acute GVHD and subsequently chronic GVHD). The CD8-HDM Cell Separation System appears to be highly selective and effective in depleting CD8+ T cells from DLI apheresis products, and CD8-depleted DLI is capable of mediating a graft-versus-leukemia effect while minimizing GVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Weiden PL, Sullivan K, Flournoy N et al. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529–1533.

    Article  CAS  PubMed  Google Scholar 

  2. Weiden PL, Flournoy N, Sanders JE et al. Anti-leukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplant Proc 1981; 13: 248–251.

    CAS  PubMed  Google Scholar 

  3. Odom LF, August CS, Githens JH et al. Remission of relapsed leukaemia during a graft-versus-host reaction. A ‘graft-versus-leukaemia reaction’ in man? Lancet 1978; 2: 537–540.

    Article  CAS  PubMed  Google Scholar 

  4. Higano CS, Brixey M, Bryant EM et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transfusion 1990; 50: 175–177.

    CAS  Google Scholar 

  5. Collins RH, Rogers ZR, Bennett M et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation. Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 1992; 10: 391–395.

    PubMed  Google Scholar 

  6. Abraham R, Szer J, Bardy P, Grigg A . Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants. Bone Marrow Transplant 1997; 20: 773–777.

    Article  CAS  PubMed  Google Scholar 

  7. Sanders JE, Buckner CD, Clift RA et al. Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation. Bone Marrow Transplant 1988; 3: 11–19.

    CAS  PubMed  Google Scholar 

  8. Radich JP, Sanders JE, Buckner CD et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993; 11: 304–313.

    Article  CAS  PubMed  Google Scholar 

  9. Mrsic M, Horowitz MM, Atkinson K et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992; 9: 269–275.

    CAS  PubMed  Google Scholar 

  10. Kolb H, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465.

    CAS  PubMed  Google Scholar 

  11. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041–2050.

    CAS  PubMed  Google Scholar 

  12. van Rhee F, Cullis JO, Feng L et al. Donor leukocyte transfusions (DLT) for relapse of chronic myleoid leukemia after allogeneic bone marrow transplant. Blood 1993; 82 (Suppl. 1): 416a.

    Google Scholar 

  13. Bar BMAM, Schattenberg A, Mensink EJBM et al. Donor leukocyte infusions for chronic myeloid leukemia after allogeneic bone marrow transplanation. J Clin Oncol 1993; 11: 513–519.

    Article  CAS  PubMed  Google Scholar 

  14. Porter DL, Roth MS, McGarigle C et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myelogenous leukemia. N Engl J Med 1994; 330: 100–106.

    Article  CAS  PubMed  Google Scholar 

  15. Drobyski WR, Keever CA, Roth MS et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310–2318.

    CAS  PubMed  Google Scholar 

  16. Antin JH . Graft-versus-leukemia: no longer an epiphenomenon (editorial). Blood 1993; 82: 2273–2277.

    CAS  PubMed  Google Scholar 

  17. van Rhee F, Lin F, Cullis JO et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for givien donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377–3383.

    CAS  PubMed  Google Scholar 

  18. Collins R, Shpilberg O, Drobyski W et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    Article  PubMed  Google Scholar 

  19. Champlin R, Ho W, Gajewski J et al. Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1990; 76: 418–423.

    CAS  PubMed  Google Scholar 

  20. Soiffer RJ, Gonin R, Murray C et al. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation. Blood 1993; 82: 2216–2223.

    CAS  PubMed  Google Scholar 

  21. Giralt S, Hester J, Huh Y et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337–4343.

    CAS  PubMed  Google Scholar 

  22. Alyea EP, Soiffer RJ, Canning C et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998; 91: 3671–3680.

    CAS  PubMed  Google Scholar 

  23. Centers for Disease Control. Revised guidelines for performing CD4+ T cell determinations in persons infected with human immunodeficiency virus (HIV). MMWR 1997; 42: 1–29.

  24. Bonini C, Verzeletti S, Servida P et al. Transfer of the HSV-TK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor antitumor immunity after ALLO-BMT (Meeting abstract). Blood 1994; 84: 110a.

    Google Scholar 

  25. Mackinnon S, Papadapoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261–1268.

    CAS  PubMed  Google Scholar 

  26. Dazzi F, Szydlo RM, Craddock C et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67–71.

    CAS  PubMed  Google Scholar 

  27. Shimoni A, Gajewski JA, Donato M et al. Long-term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 2001; 7: 568–575.

    Article  CAS  PubMed  Google Scholar 

  28. Soiffer RJ, Alyea EP, Hochberg E et al. Randomized trial of CD8+ T cell-depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 2002; 8: 625–632.

    Article  PubMed  Google Scholar 

  29. Claret EJ, Alyea EP, Orsini E et al. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J Clin Invest 1997; 100: 855–866.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Orsini E, Alyea EP, Schlossman R et al. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant 2000; 25: 623–632.

    Article  CAS  PubMed  Google Scholar 

  31. Zorn E, Wang KS, Hochberg EP et al. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res 2002; 8: 2052–2060.

    CAS  PubMed  Google Scholar 

  32. Wu CJ, Yang XF, McLaughlin S et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000; 106: 705–714.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Bellucci R, Wu CJ, Chiaretti S et al. Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood 2004; 103: 656–663.

    Article  CAS  PubMed  Google Scholar 

  34. Wu CJ, Chillemi A, Alyea EP et al. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood 2000; 95: 352–359.

    CAS  PubMed  Google Scholar 

  35. Yang XF, Wu CJ, Chen L et al. CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res 2002; 62: 5517–5522.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Yang XF, Wu CJ, McLaughlin S et al. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci USA 2001; 98: 7492–7497.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by NIH grant AI29530 and Biotransplant Inc. and in part by the Ted and Eileen Pasquarello Leukaemia Research Fund. Dr Soiffer is a Clinical Research Scholar of the Leukemia and Lymphoma Society.

Author information

Authors and Affiliations

  1. Department of Adult Oncology, Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, USA

    E P Alyea, C Canning, D Neuberg, H Daley & R J Soiffer

  2. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

    E P Alyea, C Canning & R J Soiffer

  3. Biotransplant Inc., Charlestown, MA, USA

    H Houde & K Atkinson

  4. University of Texas MD Anderson Cancer Center, Houston, TX, USA

    S Giralt & R Champlin

  5. Biostatistical Science, Dana-Farber Cancer Institute, Boston, USA

    D Neuberg

Authors
  1. E P Alyea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Canning
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Neuberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Daley
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Houde
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Atkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R J Soiffer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E P Alyea.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alyea, E., Canning, C., Neuberg, D. et al. CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant 34, 123–128 (2004). https://doi.org/10.1038/sj.bmt.1704536

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704536

Keywords

This article is cited by

Search

Advanced search

Quick links